Browsed by
Tag: measures

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study ?>

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

Oral OTEZLA(R) (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis. Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks; improvements…

Read More Read More

As a result, several measures of the disabilities and handicaps associated with psoriasis have been developed ?>

As a result, several measures of the disabilities and handicaps associated with psoriasis have been developed

As a result, several measures of the disabilities and handicaps associated with psoriasis have been developed. The Psoriasis Disability Index (PDI) has been shown to be sensitive to changes in the extent of lesions and to co-vary with the Sickness Impact Profile, a more general measure of the effects of disease on quality of life. Results: Although the clinical assessment was not related to patient ratings, patientrated severity scores, GHQ and PDI were correlated with each other. Factors associated with…

Read More Read More

Patients with chronic, therapy-resistant psoriasis should have access to DSC if they fail routine measures ?>

Patients with chronic, therapy-resistant psoriasis should have access to DSC if they fail routine measures

Evidence-based studies on DSC showed good clinical results and long remission periods in psoriatic patients; the two methods seem comparable in effectiveness. Patients with chronic, therapy-resistant psoriasis should have access to DSC if they fail routine measures. Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension. Melanie Calvert, PhD; Jane Blazeby, MD; Douglas G. Altman, DSc; Evidence should be cited of the reliability and validity of the PRO measure used in the trial so that readers can access…

Read More Read More